Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2025)
Ginkgo Bioworks Holdings' Income from Continuing Operations history spans 6 years, with the latest figure at 80751000.0 for Q4 2025.
- For Q4 2025, Income from Continuing Operations rose 24.91% year-over-year to 80751000.0; the TTM value through Dec 2025 reached 312763000.0, up 42.83%, while the annual FY2025 figure was 312763000.0, 42.83% up from the prior year.
- Income from Continuing Operations reached 80751000.0 in Q4 2025 per DNA's latest filing, roughly flat from 80755000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 54464000.0 in Q2 2021 to a low of 1604995000.0 in Q4 2021.
- Average Income from Continuing Operations over 5 years is 284783750.0, with a median of 169494500.0 recorded in 2022.
- Peak YoY movement for Income from Continuing Operations: tumbled 3503.81% in 2021, then skyrocketed 89.22% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 1604995000.0 in 2021, then surged by 89.22% to 173078000.0 in 2022, then decreased by 22.31% to 211694000.0 in 2023, then skyrocketed by 49.2% to 107534000.0 in 2024, then rose by 24.91% to 80751000.0 in 2025.
- Per Business Quant, the three most recent readings for DNA's Income from Continuing Operations are 80751000.0 (Q4 2025), 80755000.0 (Q3 2025), and 60300000.0 (Q2 2025).